Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology Niche tech unlocks the power of Turn science for other parts of body News provided by Share this article Share this article MOUNTAIN VIEW, Calif., Feb. 3, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging. The artificial niche replicates the environment of muscle stem cells through enriched media and structural support via engineered muscle fibers (EMFs). This confocal microscopy image shows how EMFs replicate the shape and collagen content (green) of a muscle fiber (myofiber) to tether isolated muscle stem cells (blue). High resolution electron micrographs on right confirm muscle stem cell anchoring. (Source: Turn Biotechnologies)